FBXO27

Across TCGA pan-cancer cohorts, FBXO27 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated FBXO27 data layer compared with 23 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher FBXO27 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated FBXO27 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

LIHC, ESCA, and UCEC are the cancer types where FBXO27 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.044	0.553	<.001	12	view →
ESCA	OS	Median	All	0.141	0.700	.001	9	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
STAD	DFS	Median	All	0.211	0.709	.015	6	view →
BLCA	DFS	Median	All	1.000	0.500	.031	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

FBXO27–LIHC (DFS)

Open the LIHC breakdown →